Cumulative side effects
| Side effect . | 2-CdA + P 126 patients . | Chl + P 103 patients . | P . | ||
|---|---|---|---|---|---|
| Grade III/IV (%) . | Total (%) . | Grade III/IV (%) . | Total (%) . | ||
| Thrombocytopenia | 11 (9) | 45 (36%) | 6 (6) | 28 (27) | .2 |
| Granulocytopenia | 11 (9) | 29 (23%) | 4 (4) | 11 (11) | .02 |
| Anemia | 3 (2) | 10 (8%) | 0 | 11 (11) | .6 |
| AIHA | 7 (6) | 2 (2) | .3 | ||
| Eosinophilia | 11 (9) | 5 (5) | .4 | ||
| Infection and FUO | 71 (56) | 41 (40) | .02 | ||
| Hepatic | 7 (6) | 4 (4) | .7 | ||
| Diarrhea | 3 (2) | — | |||
| Nausea/vomiting | 2 (2) | — | |||
| Skin reaction | 8 (6) | 1 | .06 | ||
| CNS | 3 (2) | — | |||
| Neuropathy | 2 (2) | 1 | .7 | ||
| Hair loss | 1 | — | |||
| Cardiac | 2 | — | |||
| PRCA | 1 | — | |||
| Renal | 1 | 1 | |||
| Side effect . | 2-CdA + P 126 patients . | Chl + P 103 patients . | P . | ||
|---|---|---|---|---|---|
| Grade III/IV (%) . | Total (%) . | Grade III/IV (%) . | Total (%) . | ||
| Thrombocytopenia | 11 (9) | 45 (36%) | 6 (6) | 28 (27) | .2 |
| Granulocytopenia | 11 (9) | 29 (23%) | 4 (4) | 11 (11) | .02 |
| Anemia | 3 (2) | 10 (8%) | 0 | 11 (11) | .6 |
| AIHA | 7 (6) | 2 (2) | .3 | ||
| Eosinophilia | 11 (9) | 5 (5) | .4 | ||
| Infection and FUO | 71 (56) | 41 (40) | .02 | ||
| Hepatic | 7 (6) | 4 (4) | .7 | ||
| Diarrhea | 3 (2) | — | |||
| Nausea/vomiting | 2 (2) | — | |||
| Skin reaction | 8 (6) | 1 | .06 | ||
| CNS | 3 (2) | — | |||
| Neuropathy | 2 (2) | 1 | .7 | ||
| Hair loss | 1 | — | |||
| Cardiac | 2 | — | |||
| PRCA | 1 | — | |||
| Renal | 1 | 1 | |||
FUO, fever of unknown origin; CNS, central nervous system; PRCA, pure red cell aplasia.